Background: Fetal echocardiography is an important method in prenatal diagnosis of Congenital Heart Disease (CHD). Fetal cardiac axis can be used as a reliable parameter in the diagnosis of CHD. The objective of this study was to discuss the abnormal fetal cardiac axis in the diagnostic value of fetal congenital heart disease.
Methods: In a 3-year period, 296 women with 20 and 40 weeks' singleton gestations referred for perinatal ultrasound consultation underwent evaluation of the fetal cardiac axis. For measurement of fetal cardiac axis, the chest axial image was obtained at the level of the four-chamber view. Of the 296 pregnancies, 260 healthy pregnancies were categorized as Group A while 36 pregnancies with severe heart disease were Group B. Cardiac anomaly was confirmed either by neonatal echocardiography or autopsy.
Results: Cardiac anomaly has been found in 36 women, 24 had abnormal axis (three with axis smaller than normal; 21 with axis larger than normal). The mean of cardiac axis for Group A (38.1±7.6°) was significantly smaller than that of Group B (52.6±19.8°) (P<0.001). The cardiac axis was independent from gestational age. With two standard deviations above and below the mean of Group A as normal cardiac axis (22.9°-53.5°), abnormal fetuses were defined as having axis < 23° or > 54°. There were 6 cases (2.3%) of cardiac axis larger than normal and no case (0%) smaller in group A, and 21 cases (58.3%) larger and 3 cases (8.3%) smaller in group B. The difference in two groups of patients with abnormal cardiac axis was statistically significant (P<0.01). The incidence of abnormal cardiac axis of group A was less than group B.
Conclusions: The measurement of fetal cardiac axis is simple and effective. Any larger or smaller fetal cardiac axis than normal is suggestive of a cardiac anomaly and requires further investigation. Four-chamber view is an important plane of fetal echocardiography.
Keywords: Fetus, cardiac, congenital, heart disease, autopsy, echocardiography.
Pharmacogenetics of Statins Therapy
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Benefits of Olive Oil Phenolic Compounds in Disease Prevention
Endocrine, Metabolic & Immune Disorders - Drug Targets Salvaging the Ischemic Heart: Gi-Coupled Receptors in Mast Cells Activate a PKCε/ALDH2 Pathway Providing Anti-RAS Cardioprotection
Current Medicinal Chemistry Statins in Aortic Stenosis
Current Pharmaceutical Design Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Type 2 Diabetes As An Inflammatory Cardiovascular Disorder
Current Molecular Medicine Chitosan as a Dietary Supplement for Weight Loss: A Review
Current Nutrition & Food Science Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine (Discontinued) Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Diabetic Complications and Insight into Antidiabetic Potentialities of Ethno- Medicinal Plants: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Current Status of Carotid Stenting
Current Vascular Pharmacology Application of Dual-Source CT Coronary Angiography in Type 2 Diabetic Patients with Symptomatic Coronary Heart Disease
Current Vascular Pharmacology Gadolinium-Deferasirox-D-Glucosamine: Novel Anti-Tumor and MR Molecular (Theranostic) Imaging Agent